Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Daver, Naval  [Clear All Filters]
Journal Article
Oran, B., and Daver, N. (2018). CheckPoint Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double Edge Sword.Biol Blood Marrow Transplant.
Daver, N., Thomas, D., Ravandi, F., Cortes, J., Garris, R., Jabbour, E., Garcia-Manero, G., Borthakur, G., Kadia, T., Rytting, M., et al. (2015). Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.Haematologica.
Srour, S.A., Saliba, R.M., Bittencourt, M.Cb, Perez, J.Miguel Ram, Kongtim, P., Alousi, A., Al-Atrash, G., Olson, A., Betul, O., Mehta, R., et al. (2019). Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.
Ravandi, F., Assi, R., Daver, N., Benton, C.B., Kadia, T., Thompson, P.A., Borthakur, G., Alvarado, Y., Jabbour, E.J., Konopleva, M., et al. (2019). Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Lancet Haematol.
Ghanem, H., Garcia-Manero, G., Faderl, S., Ravandi, F., Cortes, J., Katragadda, L., O'Brien, S., Daver, N., Pierce, S., Kadia, T., et al. (2014). Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure.Ther Adv Hematol5, 29-34.
Oran, B., Garcia-Manero, G., Saliba, R.M., Alfayez, M., Al-Atrash, G., Ciurea, S.O., Jabbour, E.J., Mehta, R.S., Popat, U.R., Ravandi, F., et al. (2020). Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.Cancer.
Sasaki, K., Strom, S.S., O'Brien, S., Jabbour, E., Ravandi, F., Konopleva, M., Borthakur, G., Pemmaraju, N., Daver, N., Jain, P., et al. (2015). Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.Lancet Haematol2, e186-93.
Sasaki, K., Kantarjian, H.M., Kadia, T., Patel, K., Loghavi, S., Garcia-Manero, G., Jabbour, E.J., DiNardo, C., Pemmaraju, N., Daver, N., et al. (2019). Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.Cancer.